3. Remarks

Applicants acknowledge that claims 15, 16, 23-25, 29, 31, 32 and 36 are pending in the application with claims 15, 16, 29, and 31 being in independent form.

The Examiner suggested amending claims 16 and 31 to be in independent form in order to rectify the asserted 112, 2nd paragraph issue. Applicants have amended the claims as suggested by the Examiner.

Claim 30 has been canceled and replaced with claim 38, which specifies that hematopoietic stem or progenitor cells used in claims 15, 16, 29, and 31 have been enriched for the CD34+ phenotype. In addition, new claim 37 has been added to specify that the flt3-ligand used in claim 31 is human flt3-ligand.

Applicants respectfully request reconsideration of the pending claims in light of the amendments presented above. If the Examiner believes that any issues could be resolved, or if the prosecution of the application could be expedited, by a telephone conference, Applicants invite the Examiner to telephone the undersigned at telephone number (206) 265-7145.

Respectfully submitted,

Yames E. Klaniecki Registration No. 38,207

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-3105
Telephone: (206) 265-7145
Facsimile: (206) 233-0644

```
Ser Dys Phe Trp Phe Leu Arg Trp Ser Leu Phe Ile Val Leu Phe Thr
                  5 10 15
 Dys Dys Ser
<210, 25
<211, 19
<212, PRT
<213> synthetic construct <400+ 25
Ser Cys Glu Ser Val Asp Cys Phe Ala Asp Ser Arg Met Ala Lys Val
Sur Met Ser
<210 > 26
<211 • 19
4212 - PRT
<213> synthetic construct <400> 26
Ser Tys Val Gly Phe Phe Cys Ile Thr Gly Ser Asp Val Ala Ser Val
                                        10
Asn Ser Ser
<210> 27
<211> 19
<212> PRT
<213> synthetic construct
<400> 27
Ser Cys Ser Asp Cys Leu Lys Ser Val Asp Phe Ile Pro Ser Ser Leu
Ala Ber Ser
<210 > 28
<211 > 19
<212 > PRT
<213 synthetic construct <400 > 28
Ser Cys Ala Phe Asp Cys Pro Ser Ser Val Ala Arg Ser Pro Gly Glu
                                        10
Trp Ser Ser
<210 > 29
<211 > 16
<212 > PET
<713     synthetic construct
<400     29</pre>
Ser Cys Val Asp Val Met His Ala Asp Ser Pro Gly Pro Asp Gly Lou
                                        10
Asn Sei
```